ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: A potential candidate drug with anti-inflammatory properties is the tyrosine kinase inhibitor (TKI) imatinib, which was originally developed to target the tumor-associated fusion protein BCR-Abl in chronic myelogenous leukemia (CML).